NCT05034952View on ClinicalTrials.gov

A Study Evaluating Efficacy and Safety of VX-548 for Acute Pain After an Abdominoplasty

PHASE2CompletedINTERVENTIONAL
Enrollment

303

Participants

Timeline

Start Date

August 30, 2021

Primary Completion Date

December 5, 2021

Study Completion Date

December 21, 2021

Conditions
Acute Pain
Interventions
DRUG

VX-548

Tablets for oral administration.

DRUG

HB/APAP

Capsules for oral administration.

DRUG

Placebo (matched to VX-548)

Placebo matched to VX-548 for oral administration.

DRUG

Placebo (matched to HB/APAP)

Placebo matched to HB/APAP for oral administration.

Trial Locations (7)

21122

Chesapeake Research Group, Pasadena

45417

Midwest Clinical Research Center, Dayton

77401

First Surgical Hospital, Bellaire

78229

Endeavor Clinical Trials, San Antonio

84107

JBR Clinical Research, Salt Lake City

85053

Arizona Research Center, Phoenix

91105

Lotus Clinical Research, Pasadena

All Listed Sponsors
lead

Vertex Pharmaceuticals Incorporated

INDUSTRY

NCT05034952 - A Study Evaluating Efficacy and Safety of VX-548 for Acute Pain After an Abdominoplasty | Biotech Hunter | Biotech Hunter